Market Overview

UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram

Share:
Related CVS
CVS Pharmacy To Launch Digital Receipts For Customers
CVS Health Q1'16 Earnings Conference Call: Full Transcript
Procter & Gamble Is No Longer A Growth Stock (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS), but removed the $65.00 price target.

In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.”

CVS/Caremark closed on Wednesday at $66.76.

Latest Ratings for CVS

DateFirmActionFromTo
May 2016JefferiesMaintainsBuy
May 2016CitigroupMaintainsNeutral
Mar 2016Credit SuisseAssumesOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!